Zoetis Inc. — FY2016 Form 10-K
Reporting period: Fiscal year ended December 31, 2016. The filing also provides unaudited fourth-quarter results. Zoetis is a global animal-health medicines and vaccines company, reporting U.S. and International operating segments; contract manufacturing is reported separately.
Financial performance and liquidity
| Metric | FY2016 | FY2015 |
|---|---|---|
| Revenue | $4.888 billion | $4.765 billion |
| Net income attributable to Zoetis | $821 million | $339 million |
| Diluted EPS | $1.65 | $0.68 |
| Adjusted net income (non-GAAP) | $975 million | $889 million |
| Operating cash flow | $713 million | $664 million |
| Cash and cash equivalents at year-end | $727 million | $1.154 billion |
| Long-term debt at year-end | $4.468 billion | $4.463 billion |
- Revenue rose 3% reported and 5% excluding foreign exchange. Foreign exchange reduced reported growth by about 2%.
- Gross margin was approximately 65.9% (revenue less cost of sales); cost of sales was 34% of revenue, versus 36% in 2015. Segment gross margins were 77.5% in the U.S. and 65.1% International.
- Net income margin was approximately 16.8%, versus 7.1% in 2015. The sharp GAAP increase partly reflects unusually high 2015 restructuring, stand-up and Venezuela-related charges; adjusted net income increased 10%.
- Companion-animal revenue grew 11% to $1.956 billion; livestock revenue fell 3% to $2.881 billion. U.S. revenue increased 5%; International revenue was nearly flat reported, with 5% operational growth offset by foreign exchange.
- Investing cash outflow was $214 million, including $216 million of capital spending and $88 million of acquisitions, partly offset by asset-sale proceeds. Financing cash outflow was $903 million, including debt repayment, share repurchases and dividends. Operating cash flow less capital spending was approximately $497 million.
- Year-end working capital was $2.273 billion and the current ratio was 3.03:1. The $1.0 billion revolving credit facility and $1.0 billion commercial-paper program had no amounts outstanding; the company reported compliance with debt covenants.
- Quarterly FY2016 fourth-quarter revenue was $1.277 billion, net income attributable to Zoetis was $154 million and diluted EPS was $0.31, compared with $1.274 billion, $22 million and $0.04, respectively, in Q4 2015.
Material changes and notable items
- Growth was led by Apoquel and new launches, including Cytopoint and Simparica, alongside acquired businesses. Product and market rationalization under the efficiency program reduced operational revenue by about 5%.
- SG&A fell 11% to $1.364 billion, and cost of sales declined 4%; management attributed the changes in part to efficiency actions, lower stand-up costs and favorable mix. R&D expense increased 3% to $376 million.
- Interest expense rose 34% to $166 million, principally following the November 2015 issuance of $1.25 billion in senior notes. A $400 million note matured and was repaid in February 2016.
- The effective tax rate was 33.3%, down from 37.8% in 2015. FY2016 included an approximately $35 million net tax charge related to the European Commission’s decision on Belgium’s excess-profits ruling.
- Other income/deductions included a $26 million net gain on certain divestitures, a $14 million Mexico commercial-settlement charge and a $15 million Egyptian-pound devaluation charge. The $89 million Venezuela remeasurement loss occurred in 2015, materially affecting the comparison.
Outlook, risks and contingencies
- The filing describes growth priorities—new products and lifecycle innovation, emerging markets, operational efficiency and complementary businesses—but provides no clear numerical FY2017 guidance in the supplied text.
- The efficiency program targeted elimination of approximately 2,000–2,500 positions and exit or sale of ten manufacturing sites over time. About 1,800 positions had been eliminated by year-end 2016; further reductions were expected primarily over the following six months.
- Key risks include restrictions on livestock antibacterials (about $1.3 billion of FY2016 revenue), foreign exchange and currency controls, animal-disease outbreaks, generic competition, customer consolidation, product safety or supply disruptions, regulatory and R&D uncertainty, and execution of restructuring and acquisitions.
- Zoetis reported approximately $4.5 billion of unsecured debt. Debt covenants, refinancing needs and cash-access or repatriation restrictions are relevant liquidity considerations. Management stated it expected cash, operating cash flows and financing arrangements to support foreseeable needs.
- Legal matters include approximately 259 PregSure-related claims, environmental proceedings in Brazil and litigation relating to contaminated animal feed; management said it could not estimate reasonably possible losses in excess of accrued amounts. It considered material adverse effects from proceedings remote overall, while noting individual unfavorable outcomes could be material.
- KPMG issued unqualified opinions on the financial statements and internal control over financial reporting as of December 31, 2016.
Important facts for investors to verify
- How much of earnings growth reflects sustainable operating improvement versus the unusually large 2015 charges and FY2016 tax, divestiture and settlement items.
- Whether companion-animal growth, especially Apoquel and new launches, can offset livestock declines and product rationalization.
- Progress, remaining costs and realized savings from workforce reductions and planned manufacturing-site exits.
- Debt maturities, interest costs, capital returns and covenant headroom alongside cash generation and working-capital needs.
- Exposure to antimicrobial-use restrictions, currency movements, tax disputes and the disclosed legal and environmental matters.